One-Year Results Of Direct Selective Laser Trabeculoplasty In Routine Clinical Practice.
Published 2025 - 43rd Congress of the ESCRS
Reference: PO681 | Type: Free paper | DOI: 10.82333/szag-h565
Authors: Keith Barton* 1 , Christopher Engleman 2 , Robert Chang 3 , Shienal Patel 3 , Rohit Varma 4
1Professor of Ophthalmology,University College London,London,United Kingdom;Consultant Ophthalmic Surgeon, Glaucoma Service,Moorfields Eye Hospital,London,United Kingdom, 2Ophthalmology ,Stanford University,Stanford,United States;Glaucoma,Spectrum Eye Physicians,Los Gatos,United States, 3Myra Vision,Campbell,United States, 4Ophthalmology ,Southern California Eye Institute,Los Angeles,United States
Purpose
To evaluate changes in intraocular pressure (IOP) and hypotensive medical treatment in patients treated with direct selective laser trabeculoplasty (DSLT).
Setting
A retrospective analysis was conducted on patients with ocular hypertension or open-angle glaucoma treated with DSLT, with a minimum follow-up of one year. These patients were not selected based on specific inclusion criteria other than meeting the optimal clinical assessment for laser treatment eligibility and providing informed consent for its application.
Methods
The primary study variables were changes in IOP at one month, six months, and one year, as well as modifications in hypotensive treatment. Patients were categorized into three groups: Group 1 (first-line treatment), group 2 (medication-sparing treatment), and Group 3 (patients requiring an increase in hypotensive treatment).
Results
The analysis included data from 49 treated eyes: 12 treatment-naïve patients, 23 eyes in group 2, and 14 eyes in Group 3. In Group 1, with a pre-treatment mean IOP of 26.5 mmHg, the IOP reduction at one month, six months, and one year was -24%, -20%, and -19%, respectively, with 83% of patients remaining off medication. In Group 2, the initial mean IOP was 15.1 mmHg, with an average of two hypotensive drugs. IOP remained stable throughout follow-up, while medication use decreased by 30% at one month and 37% at both six months and one year. In Group 3, the pre-treatment mean IOP was 20.41 mmHg, with an average of 1.75 medications. IOP changes were -16.4%, -22.8%, and -15% at the three follow-up periods, with stable medical treatment.
Conclusions
DSLT treatment reduces IOP and/or the need for hypotensive medications in patients with ocular hypertension and open-angle glaucoma. Further studies are needed to assess the medium- and long-term efficacy of this treatment in routine clinical practice.